What is the 13F Pro Quality Score for ATNM?

13F Pro ranks Actinium Pharmaceuticals, Inc. (ATNM) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ATNM's current score at https://13fpro.ai/research/ATNM (free sign-up required for the full ranking).

Where does 13F Pro source ATNM data?

All Actinium Pharmaceuticals, Inc. fundamentals and ownership data come directly from SEC EDGAR. Actinium Pharmaceuticals, Inc. files with the SEC under CIK 1388320. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ATNM in?

Actinium Pharmaceuticals, Inc. (ATNM) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ATNM research updated on 13F Pro?

ATNM's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Actinium Pharmaceuticals, Inc.(ATNM)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 1388320 ATNM stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $1.1M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

ATNM Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Actinium Pharmaceuticals, Inc. (ATNM), a Healthcare sector company. ATNM is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $1.1m in revenue. Based on the latest XBRL financial filings (Q1 2026), Actinium Pharmaceuticals, Inc. reports net income of $-5.5M, free cash flow of $-5.9M. Top institutional holders of ATNM by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, MILLENNIUM MANAGEMENT, RENAISSANCE TECHNOLOGIES, based on the most recent SEC filings. ATNM trades on the NYSE exchange and files with the SEC under CIK 1388320. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ATNM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Actinium Pharmaceuticals, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-5.5M

Free Cash Flow

Q1 2026

$-5.9M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

$90.0KFY 2025

FY22 $1.0MFY23 $81.0KFY24 —FY25 $90.0K

Net Income

+11.4% YoY

$-33.9MFY 2025

FY22 $-33.0MFY23 $-48.8MFY24 $-38.2MFY25 $-33.9M

Operating Income

+13.9% YoY

$-36.2MFY 2025

FY22 $-34.1MFY23 $-51.9MFY24 $-42.1MFY25 $-36.2M

EPS (Diluted)

+14.2% YoY

$-1.09FY 2025

FY22 $-1.37FY23 $-1.83FY24 $-1.27FY25 $-1.09

Total Assets

-32.7% YoY

$51.8MFY 2025

FY22 $114.2MFY23 $81.4MFY24 $76.9MFY25 $51.8M

Op. Cash Flow

+25.7% YoY

$-24.6MFY 2025

FY22 $8.6MFY23 $-47.3MFY24 $-33.1MFY25 $-24.6M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2020	FY 2018
Revenue	$90.0K	—	$81.0K -92.1%	$1.0M	—	—
Net Income	$-33.9M +11.4%	$-38.2M +21.7%	$-48.8M -47.9%	$-33.0M -48.6%	$-22.2M +6.1%	$-23.7M
Operating Income	$-36.2M +13.9%	$-42.1M +18.9%	$-51.9M -52.2%	$-34.1M -52.3%	$-22.4M +6.0%	$-23.8M
EPS (Diluted)	$-1.09 +14.2%	$-1.27 +30.6%	$-1.83 -33.6%	$-1.37	—	—
Total Assets	$51.8M -32.7%	$76.9M -5.6%	$81.4M -28.7%	$114.2M +72.0%	$66.4M +345.9%	$14.9M
Operating Cash Flow	$-24.6M +25.7%	$-33.1M +30.1%	$-47.3M -647.6%	$8.6M +140.0%	$-21.6M -5.1%	$-20.6M

AI Insight: ATNM Financial Trends

Equity has collapsed from $44M to $2M in six quarters as persistent operating losses consume cash with no revenue in sight.

• Equity eroded from $44M in Q2 2024 to $2M in Q1 2026, an $42M destruction over six quarters.

• Operating losses have persisted every quarter, ranging from -$6M to -$17M, with zero revenue recorded throughout.

• Operating cash outflows moderated slightly to -$5M in Q2 2025 and -$5M in Q4 2025, versus -$12M in Q3 2024.

⚠ Equity at $2M in Q1 2026 signals near-insolvency; any further quarterly loss risks negative book value.

⚠ No revenue across all reported periods — first meaningful revenue recognition would be a critical inflection point to monitor.

⚠ Absence of debt data obscures true leverage; undisclosed liabilities could accelerate balance-sheet deterioration.

AI Insight: ATNM Ratio Trends

Actinium remains deeply loss-making with ROA consistently negative across all reported quarters, offering no profitability inflection yet.

• ROA deteriorated sharply from -50.5% in Q2 2024 to -92.9% in Q1 2025 before partially recovering to -48.6% in Q1 2026.

• ROE deepened from -103.6% in Q2 2024 to -148.9% in Q3 2025, signaling accelerating equity erosion over the period.

• OpMargin, NPM, ROIC, and D/E are absent across nearly all periods, limiting visibility into cost structure and leverage.

⚠ ROA of -48.6% in Q1 2026 is the least negative in five quarters — monitor whether this partial recovery continues.

⚠ ROIC data available only for Q4 2024 at -91.6%; absence of subsequent readings obscures capital efficiency trajectory.

Get alerted when ATNM's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Actinium Pharmaceuticals, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ATNM

VANGUARD CAPITAL MANAGEMENT LLC
$1.2M1,255,516 sh
MILLENNIUM MANAGEMENT LLC
$561.9K564,600 sh
RENAISSANCE TECHNOLOGIES LLC
$469.4K471,600 sh
BlackRock, Inc.
$369.5K371,210 sh
TWO SIGMA INVESTMENTS, LP
$335.6K337,168 sh
GEODE CAPITAL MANAGEMENT, LLC
$334.6K336,073 sh
GAGNON SECURITIES LLC
$200.4K201,300 sh
VANGUARD FIDUCIARY TRUST CO
$159.5K160,265 sh
STATE STREET CORP
$125.6K126,215 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$123.4K123,998 sh

Fund	Value	Shares
VANGUARD CAPITAL MANAGEMENT LLC	$1.2M	1,255,516
MILLENNIUM MANAGEMENT LLC	$561.9K	564,600
RENAISSANCE TECHNOLOGIES LLC	$469.4K	471,600
BlackRock, Inc.	$369.5K	371,210
TWO SIGMA INVESTMENTS, LP	$335.6K	337,168
GEODE CAPITAL MANAGEMENT, LLC	$334.6K	336,073
GAGNON SECURITIES LLC	$200.4K	201,300
VANGUARD FIDUCIARY TRUST CO	$159.5K	160,265
STATE STREET CORP	$125.6K	126,215
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$123.4K	123,998

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ATNM on your watchlist

Track score changes the day Actinium Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ATNM a good stock to buy?

13F Pro's AI-powered analysis of Actinium Pharmaceuticals, Inc. (ATNM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ATNM are available on the ATNM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ATNM?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ATNM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Actinium Pharmaceuticals, Inc.'s investment landscape.